GlassScriptPhysician profile
Murugavel Muthusamy
NPI 1467420760
$12,046.96
in general payments reported to CMS, 2019-2025
67 companies · $860 in 2025
The $860 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $955 · 2020: $224 · 2021: $5,606 · 2022: $3,619 · 2024: $783 · 2025: $860.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,543 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,543.10 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,395.14 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $1,218.20 | 2019-2025 | Opdivo, Cobenfy |
| Incyte Corporation | $735.41 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $723.68 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $536.40 | 2019-2025 | Keytruda, Keytruda Qlex |
| Seagen INC. | $535.04 | 2020-2022 | |
| Celgene Corporation | $462.37 | 2019-2022 | |
| Beigene USA, INC. | $399.25 | 2021-2022 | |
| Pfizer INC. | $373.98 | 2019-2024 | |
| Pharmacyclics LLC, An Abbvie Company | $330.91 | 2019-2022 | |
| Genzyme Corporation | $330.11 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $305.25 | 2021-2025 | Imfinzi, Datroway, Tagrisso |
| Janssen Biotech, INC. | $275.36 | 2019-2024 | |
| Eisai INC. | $249.67 | 2021-2022 | |
| Puma Biotechnology, INC. | $239.72 | 2019-2022 |
Show all 67 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Murugavel Muthusamy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.